How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

849 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease

Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease '); } else { document.write(' '); } ACE | Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease Search > > Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease - Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease Published on 5 February 2018 (...) Guidance Recommendation The Ministry of Health's Drug Advisory Committee has recommended: Rivastigmine patch formulation (4.6mg/24h and 9.5mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Parkinson's disease. Rivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Alzheimer's disease. Conditions should be confirmed

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

2. How to minimise the risks of medication errors with rivastigmine patches

How to minimise the risks of medication errors with rivastigmine patches How to minimise the risks of medication errors with rivastigmine patches – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · 29th March 2019 This updated Q&A aims to raise awareness on the types of medication errors reported with rivastigmine patches, as well as highlighting strategies to improve medication safety on the prescribing and administration of these patches

2019 Specialist Pharmacy Services

3. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study Full Text available with Trip Pro

Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports. Our goal was to investigate the 30-day risk of admission to hospital with rhabdomyolysis (...) associated with initiating donepezil versus other cholinesterase inhibitors.We conducted a retrospective cohort study in Ontario, Canada, from 2002 to 2017. Participants were adults aged 66 years or older with a newly dispensed prescription for donepezil compared with rivastigmine or galantamine. The primary outcome was hospital admission with rhabdomyolysis (assessed using hospital diagnostic codes) within 30 days of a new prescription of a cholinesterase inhibitor. Odds ratios were estimated using

2019 EvidenceUpdates

4. Rivastigmine for Alzheimer's disease. Full Text available with Trip Pro

Rivastigmine for Alzheimer's disease. Alzheimer's disease is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose (...) , was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and lower risk of adverse effects have since been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA.To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type.We searched ALOIS, the Cochrane

2015 Cochrane

5. How to minimise the risks of medication errors with rivastigmine patches

How to minimise the risks of medication errors with rivastigmine patches application/msword

2017 Specialist Pharmacy Services

6. Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. (Abstract)

Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. Although an optimized delivery of rivastigmine for management of Alzhiemer disease (AD) is provided by the transdermal patch, it is critical to establish a limited sampling strategy for the measurement of exposure of rivastigmine/NAP226-90.The relationship Cmax versus AUC0-24h for rivastigmine/NAP226-90 (...) was established by regression models. The derived regression equations enabled the prediction AUC0-24h for rivastigmine and NAP226-90. Models were evaluated using statistical criteria. Mixed model was used to predict AUC0-24h for rivastigmine/NAP226-90 from time points such as 8 (C8h), 12 (C12h), and 18 (C18h) hours.Excellent correlation was established for between Cmax and AUC0-24h for rivastigmine and NAP226-90. AUC0-24h predictions of either rivastigmine or NAP226-90 were within 0.8- to 1.25-fold

2017 Clinical neuropharmacology Controlled trial quality: uncertain

7. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. Full Text available with Trip Pro

Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. Rivastigmine (Riv) is a potent and selective cholinesterase (acetylcholinesterase, AChE and butyrylcholinesterase, BuChE) inhibitor developed for the treatment of Alzheimer's disease (AD). To elucidate whether Riv causes neuronal differentiation, we examined its effect on nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. At concentrations

2018 PLoS ONE

8. Rivastigmine 3M Health Care Ltd

Rivastigmine 3M Health Care Ltd EMA/58565/2014 EMEA/H/C/003824 EPAR summary for the public Rivastigmine 3M Health Care Ltd rivastigmine This is a summary of the European public assessment report (EPAR) for Rivastigmine 3M Health Care Ltd. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rivastigmine 3M Health Care Ltd. For practical information about using (...) Rivastigmine 3M Health Care Ltd, patients should read the package leaflet or contact their doctor or pharmacist. What is Rivastigmine 3M Health Care Ltd and what is it used for? Rivastigmine 3M Health Care Ltd is a medicine that contains the active substance rivastigmine. Rivastigmine 3M Health Care Ltd is used to treat patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. Rivastigmine 3M Health Care Ltd

2014 European Medicines Agency - EPARs

9. Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial. (Abstract)

Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial. To treat patients with bipolar disorders (BPD) during the acute phase, the standard procedure is to administer lithium or sodium valproate. To further optimize treatment, acetylcholinesterase inhibitors such as donepezil and galantamine have gained increased interest, though with conflicting (...) results. In the present randomized, double-blind, placebo-controlled clinical trial, we investigated whether, and to what extent, adjuvant rivastigmine might improve symptoms of mania in patients with BPD during the acute manic phase.A total of 70 patients with BPD in an acute state of mania (mean age 33.8 years; 24% females) took part in this study. After a thorough clinical interview, standard treatment consisted of 20mg/kg/day of sodium valproate; next, patients were randomly assigned either

2019 Neuropsychobiology Controlled trial quality: uncertain

10. Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. Full Text available with Trip Pro

Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. An important challenge in schizophrenia therapeutics is to develop an efficacious treatment for cognitive impairment. Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients.Rivastigmine (uptitrated to 6 mg/day) was given as an add-on therapy to risperidone-treated stable (...) schizophrenia patients in a randomized, double-blind, placebo-controlled design. Of 67 patients who met eligibility criteria, 55 were recruited into the study. Twenty-eight were assigned to rivastigmine and 27 to placebo. These patients completed tests of attention, executive functioning, verbal skills, verbal and visuospatial working memory, and psychomotor speed on five occasions: at baseline, and at the end of the 1st, 3rd, 6th, and 12th months.The groups were similar in terms of sociodemographic profile

2019 Indian journal of psychiatry Controlled trial quality: uncertain

11. Rivastigmine does not alter cocaine-induced subjective effects or self-administration. (Abstract)

Rivastigmine does not alter cocaine-induced subjective effects or self-administration. Acetylcholinergic (ACh) neurons interface with the mesolimbic dopamine pathway implicated in addiction, and acetylcholinesterase inhibitors (AChEis) have been shown to reduce the immediate effects of cocaine and amount used. Our study is the first to examine if the safe and low-interaction AChEi rivastigmine (riv) alters the subjective effects produced by cocaine administration.Cocaine-dependent subjects were (...) subjects were randomized to placebo (n = 16), riv 3 mg (n = 13), or riv 6 mg (n = 12). All subjects completed the study and there were no demographic differences between treatment groups. Pre- and post- treatment, there were no significant pharmacokinetic differences (blood levels of cocaine, BE, EME) following cocaine administration. In a two-way ANOVA, IV cocaine significantly increased positive VAS category ratings compared to placebo, but rivastigmine treatment at either dose had no significant

2019 Pharmacology, biochemistry, and behavior Controlled trial quality: uncertain

12. Cholinesterase inhibitors in Alzheimer's disease: supplementary commission rivastigmine patches and galantamine

Cholinesterase inhibitors in Alzheimer's disease: supplementary commission rivastigmine patches and galantamine Executive Summary 1 Translation of the executive summary of the final report “Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin” (Version 1.0; Status: 03.02.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports - Commission No. A09-05 Cholinesterase inhibitors in Alzheimer’s disease: supplementary commission rivastigmine patches and galantamine 1 Executive summary of final report A09-05 Version 1.0 Cholinesterase inhibitors – rivastigmine patches/galantamine 03.02.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cholinesterase inhibitors in Alzheimer’s disease: supplementary

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia. (Abstract)

A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia. The objective of this study was to compare the efficacy and safety of oral and transdermal rivastigmine for postural instability in patients with Parkinson disease dementia (PDD) who were candidates for a cholinesterase inhibitor. The primary outcome was the change in mean velocity of the center of pressure (CoP) after 6 months. Secondary outcomes included structural parameters (...) of dynamic posturography, clinical rating scales, and adverse events requiring dose reduction.Patients with PDD were randomized in a 1:1 ratio to oral or transdermal rivastigmine with target doses of 6 mg twice daily and 9.5 mg/10 cm daily, respectively. Outcomes were assessed at baseline and 6 months. Results were compared within and between groups.Nineteen patients completed the study (n = 8 oral, n = 11 transdermal). Mean daily doses of 9.4 (±1.5 mg) and 16.4 (±3.6 mg) were achieved in the oral

2018 Clinical neuropharmacology Controlled trial quality: uncertain

14. Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. (Abstract)

Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. To assess the bioequivalence of generic formulation of rivastigmine (test) and Exelon (reference).This randomized, open-label, 2-period, single-dose, 2-treatment, 2-sequence, crossover study was conducted in 40 healthy men under fed condition. Participants were randomized to receive a single dose of Exelon or rivastigmine capsule.A total of 31 participants completed the study. Area under the concentration (...) -time curve from time zero to time t (AUC0- t) and area under the concentration-time curve from time zero to infinity (AUC0-∞) for Exelon (mean [standard deviation], h·ng/mL) were 126.40 (56.95) and 129.46 (59.94), respectively, while they were 122.73 (43.46) and 125.08 (45.39) for rivastigmine. Geometric mean ratios of rivastigmine/Exelon were 99.17% for AUC0- t, 98.81% for AUC0-∞, and 105% for maximum observed plasma concentration ( Cmax). The 90% confidence intervals (CIs) were 94.14% to 104.46

2018 American journal of Alzheimer's disease and other dementias Controlled trial quality: uncertain

15. Adverse drug events affecting medication persistence with rivastigmine patch application Full Text available with Trip Pro

Adverse drug events affecting medication persistence with rivastigmine patch application The rivastigmine transdermal patch, the only existing cholinesterase inhibitor available as a transdermal delivery system for treating Alzheimer's disease, has been reported to inhibit progression of cognitive impairment and impairment in activities of daily living, in addition to reducing care burden and improving adherence. However, application of the rivastigmine patch also frequently results in erythema (...) , pruritus, contact dermatitis, and other cutaneous adverse events at the application site, making it difficult to increase the effective dose and continue treatment. Therefore, we conducted a survey to examine the manifestation of adverse events and medication persistence in patients who were prescribed the rivastigmine patch.Three hundred and twelve patients diagnosed with Alzheimer's disease between July 1, 2011 and March 31, 2015 at the Toki Medical Clinic and who were prescribed a rivastigmine patch

2018 Patient preference and adherence

16. A Stability Indicating HPLC Assay Method for Analysis of Rivastigmine Hydrogen Tartrate in Dual-Ligand Nanoparticle Formulation Matrices and Cell Transport Medium Full Text available with Trip Pro

A Stability Indicating HPLC Assay Method for Analysis of Rivastigmine Hydrogen Tartrate in Dual-Ligand Nanoparticle Formulation Matrices and Cell Transport Medium The objective of this study was to develop and validate a method for quantitative analysis of rivastigmine hydrogen tartrate (RHT) in dual-ligand polymeric nanoparticle formulation matrices, drug release medium, and cellular transport medium. An isocratic HPLC analysis method using a reverse phase C18 column and a simple mobile phase

2018 Journal of analytical methods in chemistry

17. An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine Full Text available with Trip Pro

An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders worldwide. Despite all research efforts, therapeutic options for AD are still limited to two drug classes: cholinesterase inhibitors (ChEIs) and the NMDA-receptor antagonist memantine. Donepezil, rivastigmine and galantamine are the three ChEIs FDA-approved as first-line treatment for AD. Although they share the same (...) mode of action, they differ in terms of their pharmacologic characteristics and route of administration, which can impact their safety and tolerability profile. Rivastigmine, available in both oral and transdermal patch formulations, is a slowly reversible dual inhibitor of acetyl and butyryl cholinesterase, selective for the G1 isoform of acetylcholinesterase, without hepatic metabolism by the CYP-450 system. Despite its unique features, it has been associated with a higher incidence of adverse

2018 Therapeutic advances in drug safety

18. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial. Full Text available with Trip Pro

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial. Studies investigating the impact of white matter hyperintensities (WMHs) on the response of acetylcholinesterase inhibitors in patients with Alzheimer's disease (AD) have presented inconsistent results. We aimed to compare the effects of the rivastigmine (...) patch between patients with AD with minimal WMHs and those with moderate WMHs.Three hundred patients with mild to moderate AD were enrolled in this multicenter prospective open-label study and divided into two groups. Group 1 comprised patients with AD with minimal WMHs and group 2 comprised those with moderate WMHs. The patients were treated with a rivastigmine patch for 24 weeks. Efficacy measures were obtained at baseline and after 24 weeks. The primary endpoint was the change in the AD

2017 PLoS ONE

19. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. Full Text available with Trip Pro

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study. To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-associated cognitive impairment.We recruited HIV-infected patients with cognitive impairment on stable antiretroviral therapy in a randomized controlled pilot trial with a 48-week follow-up. An additional assessment was held at 12 weeks. Participants received transdermal rivastigmine (9.5 mg daily), lithium (400 mg (...) no significant differences between the arms (mean NPZ-7 change [SD]): rivastigmine, 0.35 (0.14); lithium, 0.25 (0.40); control, 0.20 (0.44) (p = 0.78). The rivastigmine group showed the highest positive trend (mean NPZ-7 [SD], baseline vs week 48): rivastigmine, -0.47 (0.22) vs -0.11 (0.29), p = 0.06; lithium, -0.50 (0.40) vs -0.26 (0.21), p = 0.22; control, -0.52 (0.34) vs -0.32 (0.52), p = 0.44. The cognitive domains with the highest positive trends were information processing speed at week 12

2017 PLoS ONE Controlled trial quality: uncertain

20. Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03659435 Recruitment Status : Recruiting

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>